Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 672.36M | 660.57M | 591.64M | 509.73M | 484.33M | 444.45M |
Gross Profit | 294.43M | 290.10M | 244.60M | 187.90M | 187.06M | 185.89M |
EBITDA | -93.00K | -1.51M | -17.61M | -82.33M | 46.50M | 34.85M |
Net Income | -77.59M | -78.73M | -87.97M | -144.25M | -8.35M | 4.17M |
Balance Sheet | ||||||
Total Assets | 1.60B | 1.64B | 1.68B | 1.74B | 1.87B | 988.33M |
Cash, Cash Equivalents and Short-Term Investments | 358.08M | 386.84M | 415.20M | 437.99M | 515.39M | 296.26M |
Total Debt | 604.78M | 605.33M | 611.68M | 610.93M | 612.79M | 218.22M |
Total Liabilities | 713.16M | 735.70M | 739.69M | 742.01M | 761.50M | 294.04M |
Stockholders Equity | 888.27M | 902.34M | 941.54M | 998.02M | 1.11B | 694.29M |
Cash Flow | ||||||
Free Cash Flow | -32.37M | -34.04M | -30.70M | -96.88M | -90.86M | -27.64M |
Operating Cash Flow | 7.61M | 7.02M | -1.95M | -65.99M | -26.72M | 1.46M |
Investing Cash Flow | 1.89M | 12.86M | 76.71M | 517.00K | -632.37M | -159.44M |
Financing Cash Flow | 4.78M | 4.65M | 4.55M | 11.83M | 725.28M | 235.60M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
74 Outperform | $1.05B | 16.92 | 21.57% | ― | 25.92% | ― | |
73 Outperform | $587.26M | 30.59 | -1.20% | ― | 38.43% | 86.19% | |
52 Neutral | $1.05B | ― | -3.04% | ― | -13.79% | 82.82% | |
52 Neutral | $606.13M | ― | -3.61% | ― | 1.71% | 76.00% | |
51 Neutral | $953.63M | ― | -8.57% | ― | 10.10% | 8.79% | |
46 Neutral | C$192.85M | -4.28 | -8.56% | 2.83% | 13.52% | -1.74% | |
45 Neutral | $509.74M | ― | -13.84% | ― | 7.38% | 60.45% |
On June 19, 2025, NeoGenomics, Inc. expanded its Board of Directors from nine to ten members and appointed Marjorie C. Green as a new director. Dr. Green, who is currently Senior Vice President and Head of Oncology, Global Clinical Development at Merck, brings extensive experience in oncology and business development. Her appointment is expected to enhance NeoGenomics’ strategic direction in the precision oncology market, aligning with the company’s mission to improve patient care.
The most recent analyst rating on (NEO) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on NeoGenomics stock, see the NEO Stock Forecast page.
On May 22, 2025, NeoGenomics, Inc. held its annual stockholders meeting where several key proposals were approved. These included an amendment to the 2023 Equity Incentive Plan, which increased the number of shares authorized for issuance and established a minimum vesting period, among other changes. Additionally, the election of nine directors to the Board and the approval of executive compensation were confirmed. The stockholders also ratified the appointment of Deloitte & Touche LLP as the independent registered public accountant.
The most recent analyst rating on (NEO) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on NeoGenomics stock, see the NEO Stock Forecast page.